Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices 23881 

If additional information is required 

contact: Ms. Lynn Bryant, Department 

Clearance Officer, United States 

Department of Justice, Policy and 

Planning Staff, Justice Management 

Division, Suite 1600, Patrick Henry 

Building, 1331 Pennsylvania, NW., 

Washington, DC 20530. 

Dated: May 18, 2009. 

Ms. Lynn Bryant, 

Department Clearance Officer, PRA, United 

States Department of Justice. 

[FR Doc. E9–11924 Filed 5–20–09; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–318P] 

Controlled Substances: Proposed 

Aggregate Production Quotas for 2010 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of proposed year 2010 

aggregate production quotas. 

SUMMARY: This notice proposes initial 

year 2010 aggregate production quotas 

for controlled substances in schedules I 

and II of the Controlled Substances Act 

(CSA). 

DATES: Comments or objections must be 

received on or before June 22, 2009. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–318P’’ on all written and 

electronic correspondence. Written 

comments should be sent to the DEA 

Headquarters, Attn: DEA Federal 

Register Representative/ODL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Comments may be directly sent 

to DEA electronically by sending an 

electronic message to 

dea.diversion.policy@usdoj.gov. 

Comments may also be sent 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the http:// 

www.regulations.gov Web site. DEA will 

accept attachments to electronic 

comments in Microsoft Word, 

WordPerfect, Adobe PDF, or Excel file 

formats only. DEA will not accept any 

file format other than those specifically 

listed here. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

8701 Morrissette Drive, Springfield, 

Virginia 22152, Telephone: (202) 307– 

7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR Section 0.100. 

The Administrator, in turn, has 

redelegated this function to the Deputy 

Administrator, pursuant to 28 CFR 

Section 0.104. 

The proposed year 2010 aggregate 

production quotas represent those 

quantities of controlled substances that 

may be produced in the United States in 

2010 to provide adequate supplies of 

each substance for: The estimated 

medical, scientific, research, and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. 

In determining the year 2010 

aggregate production quotas, the Deputy 

Administrator considered the following 

factors: Total actual 2008 and estimated 

2009 and 2010 net disposals of each 

substance by all manufacturers; 

estimates of 2009 year-end inventories 

of each substance and of any substance 

manufactured from it and trends in 

accumulation of such inventories; 

product development requirements of 

both bulk and finished dosage form 

manufacturers; projected demand as 

indicated by procurement quota 

applications filed pursuant to 21 CFR 

Section 1303.12; and other pertinent 

information. 

Pursuant to 21 CFR Section 1303, the 

Deputy Administrator of the DEA will 

adjust the 2010 aggregate production 

quotas and individual manufacturing 

quotas allocated for the year based upon 

2009 year-end inventory and actual 

2009 disposition data supplied by quota 

recipients for each basic class of 

schedule I or II controlled substance. 

Therefore, under the authority vested 

in the Attorney General by § 306 of the 

CSA of 1970 (21 U.S.C. 826), and 

delegated to the Administrator of the 

DEA by 28 CFR Section 0.100, and 

redelegated to the Deputy Administrator 

pursuant to 28 CFR Section 0.104, the 

Deputy Administrator hereby proposes 

that the year 2010 aggregate production 

quotas for the following controlled 

substances, expressed in grams of 

anhydrous acid or base, be established 

as follows: 

Basic class—schedule I Established 2010 

quotas 

2,5-Dimethoxyamphetamine ........................................................................................................................................................... 2 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................................................. 2 g 

3-Methylfentanyl .............................................................................................................................................................................. 2 g 

3-Methylthiofentanyl ........................................................................................................................................................................ 2 g 

3,4-Methylenedioxyamphetamine (MDA) ........................................................................................................................................ 25 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ......................................................................................................................... 10 g 

3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................................................. 20 g 

3,4,5-Trimethoxyamphetamine ....................................................................................................................................................... 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................. 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................. 2 g 

4-Methoxyamphetamine .................................................................................................................................................................. 27 g 

4-Methylaminorex ............................................................................................................................................................................ 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................. 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................. 2 g 

5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................. 5 g 

Acetyl-alpha-methylfentanyl ............................................................................................................................................................ 2 g 

Acetyldihydrocodeine ...................................................................................................................................................................... 2 g 

Acetylmethadol ................................................................................................................................................................................ 2 g 

Allylprodine ...................................................................................................................................................................................... 2 g 

Alphacetylmethadol ......................................................................................................................................................................... 2 g 

Alpha-ethyltryptamine ..................................................................................................................................................................... 2 g 

Alphameprodine .............................................................................................................................................................................. 2 g 

Alphamethadol ................................................................................................................................................................................ 2 g 


dwashington3 on PROD1PC60 with NOTICES
23882 Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices 

Basic class—schedule I Established 2010 

quotas 

Alpha-methylfentanyl ....................................................................................................................................................................... 2 g 

Alpha-methylthiofentanyl ................................................................................................................................................................. 2 g 

Aminorex ......................................................................................................................................................................................... 2 g 

Benzylmorphine .............................................................................................................................................................................. 2 g 

Betacetylmethadol ........................................................................................................................................................................... 2 g 

Beta-hydroxy-3-methylfentanyl ....................................................................................................................................................... 2 g 

Beta-hydroxyfentanyl ...................................................................................................................................................................... 2 g 

Betameprodine ................................................................................................................................................................................ 2 g 

Betamethadol .................................................................................................................................................................................. 2 g 

Betaprodine ..................................................................................................................................................................................... 2 g 

Bufotenine ....................................................................................................................................................................................... 3 g 

Cathinone ........................................................................................................................................................................................ 3 g 

Codeine-N-oxide ............................................................................................................................................................................. 602 g 

Diethyltryptamine ............................................................................................................................................................................ 2 g 

Difenoxin ......................................................................................................................................................................................... 3,000 g 

Dihydromorphine ............................................................................................................................................................................. 2,549,000 g 

Dimethyltryptamine ......................................................................................................................................................................... 3 g 

Gamma-hydroxybutyric acid ........................................................................................................................................................... 24,200,000 g 

Heroin .............................................................................................................................................................................................. 20 g 

Hydromorphinol ............................................................................................................................................................................... 2 g 

Hydroxypethidine ............................................................................................................................................................................ 2 g 

Ibogaine .......................................................................................................................................................................................... 1 g 

Lysergic acid diethylamide (LSD) ................................................................................................................................................... 10 g 

Marihuana ....................................................................................................................................................................................... 4,500,000 g 

Mescaline ........................................................................................................................................................................................ 7g 

Methaqualone ................................................................................................................................................................................. 5 g 

Methcathinone ................................................................................................................................................................................. 4 g 

Methyldihydromorphine ................................................................................................................................................................... 2 g 

Morphine-N-oxide ............................................................................................................................................................................ 605 g 

N-Benzylpiperazine ......................................................................................................................................................................... 2 g 

N,N-Dimethylamphetamine ............................................................................................................................................................. 7 g 

N-Ethylamphetamine ....................................................................................................................................................................... 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................. 2 g 

Noracymethadol .............................................................................................................................................................................. 2 g 

Norlevorphanol ................................................................................................................................................................................ 52 g 

Normethadone ................................................................................................................................................................................ 2 g 

Normorphine ................................................................................................................................................................................... 16 g 

Para-fluorofentanyl .......................................................................................................................................................................... 2 g 

Phenomorphan ................................................................................................................................................................................ 2 g 

Pholcodine ...................................................................................................................................................................................... 2 g 

Psilocybin ........................................................................................................................................................................................ 7 g 

Psilocyn ........................................................................................................................................................................................... 7 g 

Tetrahydrocannabinols .................................................................................................................................................................... 312,500 g 

Thiofentanyl ..................................................................................................................................................................................... 2 g 

Trimeperidine .................................................................................................................................................................................. 2 g 

Basic class—schedule II Established 2010 

quotas 

1-Phenylcyclohexylamine ................................................................................................................................................................ 2 g 

1-piperdinocyclohexanecarbonitrile ................................................................................................................................................. 2 g 

Alfentanil 8, ..................................................................................................................................................................................... 000 g 

Alphaprodine ................................................................................................................................................................................... 2 g 

Amobarbital ..................................................................................................................................................................................... 3 g 

Amphetamine (for sale) .................................................................................................................................................................. 17,000,000 g 

Amphetamine (for conversion) ........................................................................................................................................................ 5,000,000 g 

Cocaine ........................................................................................................................................................................................... 247,000 g 

Codeine (for sale) ........................................................................................................................................................................... 39,605,000 g 

Codeine (for conversion) ................................................................................................................................................................ 65,000,000 g 

Dextropropoxyphene ....................................................................................................................................................................... 106,000,000 g 

Dihydrocodeine ............................................................................................................................................................................... 1,200,000 g 

Diphenoxylate ................................................................................................................................................................................. 947,000 g 

Ecgonine ......................................................................................................................................................................................... 83,000 g 

Ethylmorphine ................................................................................................................................................................................. 2 g 

Fentanyl .......................................................................................................................................................................................... 1,428,000 g 

Glutethimide .................................................................................................................................................................................... 2 g 

Hydrocodone (for sale) ................................................................................................................................................................... 55,000,000 g 

Hydromorphone .............................................................................................................................................................................. 3,300,000 g 

Isomethadone ................................................................................................................................................................................. 2 g 

Levo-alphacetylmethadol (LAAM) ................................................................................................................................................... 3 g 

Levomethorphan ............................................................................................................................................................................. 5 g 

Levorphanol .................................................................................................................................................................................... 10,000 g 

Lisdexamfetamine ........................................................................................................................................................................... 6,200,000 g 


dwashington3 on PROD1PC60 with NOTICES
Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices 23883 

Basic class—schedule II Established 2010 

quotas 

Meperidine ...................................................................................................................................................................................... 8,600,000 g 

Meperidine Intermediate-A .............................................................................................................................................................. 3 g 

Meperidine Intermediate-B .............................................................................................................................................................. 7 g 

Meperidine Intermediate-C ............................................................................................................................................................. 3 g 

Metazocine ...................................................................................................................................................................................... 1 g 

Methadone (for sale) ....................................................................................................................................................................... 25,000,000 g 

Methadone Intermediate ................................................................................................................................................................. 26,000,000 g 

Methamphetamine .......................................................................................................................................................................... 3,130,000 g 

[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,405,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 45,000 grams for methamphetamine (for sale)] 

Methylphenidate .............................................................................................................................................................................. 50,000,000 g 

Morphine (for sale) .......................................................................................................................................................................... 35,000,000 g 

Morphine (for conversion) ............................................................................................................................................................... 100,000,000 g 

Nabilone .......................................................................................................................................................................................... 9,002 g 

Noroxymorphone (for sale) ............................................................................................................................................................. 10,000 g 

Noroxymorphone (for conversion) .................................................................................................................................................. 9,000,000 g 

Opium (powder) .............................................................................................................................................................................. 230,000 g 

Opium (tincture) .............................................................................................................................................................................. 1,050,000 g 

Oripavine ......................................................................................................................................................................................... 15,000,000 g 

Oxycodone (for sale) ...................................................................................................................................................................... 77,560,000 g 

Oxycodone (for conversion) ............................................................................................................................................................ 3,400,000 g 

Oxymorphone (for sale) .................................................................................................................................................................. 2,000,000 g 

Oxymorphone (for conversion) ....................................................................................................................................................... 12,000,000 g 

Pentobarbital ................................................................................................................................................................................... 28,000,000 g 

Phenazocine ................................................................................................................................................................................... 1 g 

Phencyclidine .................................................................................................................................................................................. 20 g 

Phenmetrazine ................................................................................................................................................................................ 2 g 

Phenylacetone ................................................................................................................................................................................ 1 g 

Racemethorphan ............................................................................................................................................................................. 2 g 

Remifentanil .................................................................................................................................................................................... 500 g 

Secobarbital .................................................................................................................................................................................... 67,000 g 

Sufentanil ........................................................................................................................................................................................ 10,300 g 

Tapentadol ...................................................................................................................................................................................... 519,000 g 

Thebaine ......................................................................................................................................................................................... 126,000,000 g 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedules I and II 

controlled substances included in 21 

CFR Sections 1308.11 and 1308.12 be 

established at zero. 

All interested persons are invited to 

submit their comments in writing or 

electronically regarding this proposal 

following the procedures in the 

‘‘ADDRESSES’’ section of this document. 

A person may object to or comment on 

the proposal relating to any of the 

above-mentioned substances without 

filing comments or objections regarding 

the others. If a person believes that one 

or more of these issues warrant a 

hearing, the individual should so state 

and summarize the reasons for this 

belief. 

In the event that comments or 

objections to this proposal raise one or 

more issues which the Deputy 

Administrator finds warrant a hearing, 

the Deputy Administrator shall order a 

public hearing by notice in the Federal 

Register, summarizing the issues to be 

heard and setting the time for the 

hearing. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of State law; nor 

does it impose enforcement 

responsibilities on any State; nor does it 

diminish the power of any State to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 


dwashington3 on PROD1PC60 with NOTICES
23884 Federal Register / Vol. 74, No. 97 / Thursday, May 21, 2009 / Notices 

Dated: May 15, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–11929 Filed 5–20–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

United States Parole Commission 

Public Announcement Pursuant to the 

Government in the Sunshine Act (Pub. 

L. 94–409) [5 U.S.C. Section 552b] 

AGENCY HOLDING MEETING: Department of 

Justice, United States Parole 

Commission. 

DATE AND TIME: 10 a.m., Thursday, May 

21, 2009. 

PLACE: U.S. Parole Commission, 5550 

Friendship Boulevard, 4th Floor, Chevy 

Chase, Maryland 20815. 

STATUS: Closed. 

MATTERS CONSIDERED: The following 

matter will be considered during the 

closed meeting: Approval or 

disapproval of a hearing examiner 

appointment. 

AGENCY CONTACT: Thomas W. 

Hutchison, Chief of Staff, United States 

Parole Commission, (301) 492–5990. 

Dated: May 14, 2009. 

Rockne Chickinell, 

General Counsel, U.S. Parole Commission. 

[FR Doc. E9–11699 Filed 5–20–09; 8:45 am] 

BILLING CODE 4410–31–M 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Interchangeable Virtual 

Instruments Foundation, Inc. 

Notice is hereby given that, on April 

10, 2009, pursuant to Section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), Interchangeable 

Virtual Instruments Foundation, Inc. 

has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Konrad GmbH, Radolfzell, 

GERMANY has been added as a party to 

this venture. Also, Vektrex Electronic 

Systems, San Diego, CA has withdrawn 

as a party to this venture. In addition, 

VXI Technology has changed its name 

to VTI Instruments, Irvine, CA. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and 

Interchangeable Virtual Instruments 

Foundation, Inc. intends to file 

additional written notifications 

disclosing all changes in membership. 

On May 29, 2001, Interchangeable 

Virtual Instruments Foundation, Inc. 

filed its original notification pursuant to 

Section 6(a) of the Act. The Department 

of Justice published a notice in the 

Federal Register pursuant to Section 

6(b) of the Act on July 30, 2001 (66 FR 

39336). 

The last notification was filed with 

the Department on January 21, 2009. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on February 26, 2009 (74 FR 8811). 

Patricia A. Brink, 

Deputy Director of Operations, Antitrust 

Division. 

[FR Doc. E9–11823 Filed 5–20–09; 8:45 am] 

BILLING CODE 4410–11–M 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—IMS Global Learning 

Consortium, Inc. 

Notice is hereby given that, on April 

16, 2009, pursuant to Section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), IMS Global Learning 

Consortium, Inc. has filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, CourseSmart, Belmont, CA; 

and American Public University 

System, Charles Town, WV have been 

added as parties to this venture. Also, 

CREDTJ Co., Ltd., Chung-Gu, Seoul, 

REPUBLIC OF KOREA has withdrawn 

as a party to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and IMS Global 

Learning Consortium, Inc. intends to file 

additional written notifications 

disclosing all changes in membership. 

On April 7, 2000, IMS Global 

Learning Consortium, Inc. filed its 

original notification pursuant to Section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to Section 6(b) of the 

Act on September 13, 2000 (65 FR 

55283) 

The last notification was filed with 

the Department on February 12, 2009. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on March 13, 2009 (74 FR 10967) 

Patricia A. Brink, 

Deputy Director of Operations, Antitrust 

Division. 

[FR Doc. E9–11824 Filed 5–20–09; 8:45 am] 

BILLING CODE 4410–11–M 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Open DeviceNet Vendor 

Association, Inc. 

Notice is hereby given that, on April 

10, 2009, pursuant to Section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), Open DeviceNet 

Vendor Association, Inc. (‘‘ODVA’’) has 

filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Microscan Systems, Inc., 

Renton, WA; B & PLUS, Saitama, 

JAPAN; Plasmart, Inc. Daejeon, Daejeon, 

REPUBLIC OF KOREA; TOKYO TRON 

CO., LTD., Tokyo-to, JAPAN; THK CO., 

LTD., Ota-ku, Tokyo, JAPAN; Alpha 

Wire Company, Elizabeth, NJ; and Delta 

Electronics, Inc., Taipei, TAIWAN have 

been added as parties to this venture. 

Also, RivaTek, Inc., Minneapolis, MN; 

Micro Motion, Inc. (Emerson Electric), 

Boulder, CO; SEC (Samsung Electronics 

Co., Ltd.), Kyungki-do, REPUBLIC OF 

KOREA; and Amphenol Alden 

Products, Brockton, MA have 

withdrawn as parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and ODVA 

intends to file additional written 

notifications disclosing all changes in 

membership. 


dwashington3 on PROD1PC60 with NOTICES